Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review
Fecha
2020Autor
Napoli, Claudio
Tritto, Isabella
Benincasa, Giuditta
Mansueto, Gelsomina
Ambrosio, Giuseppe
Documentos PDF
Resumen
SARS-CoV-2 betacoronavirus is responsible for the Corona Virus Disease 2019 (COVID-19) which has relevant
pathogenic implications for the cardiovascular system. Incidence and severity of COVID-19 are higher in the
elderly population (65 years and older). This may be due to higher frequency of comorbidities, but increased
frailty and immunosenescence linked with aging may also contribute. Moreover, in elderly individuals, SARSCoV-2 may adopt different molecular strategies to strongly impact on cardiac aging that culminate in exacerbating a pro-inflammatory state (cytokine storm activation), which, in turn, may lead to pulmonary vascular
endothelialitis, microangiopathy, diffuse thrombosis, myocarditis, heart failure, cardiac arrhythmias, and acute
coronary syndromes. All these events are particularly relevant in elderly patients, and deserve targeted cardiovascular treatments and specific management of repurposed drugs against COVID-19. We discuss current
evidence about the cardiovascular involvement during COVID-19, and elaborate on clinical implications in
elderly patients.
Palabras clave
COVID-19; SARS-Cov 2; ACE2; Inflammation; Myocarditis; Vasculitis; Heart failure; Troponin; Cytokine release syndrome; Cardiovascular drugsEnlace al recurso
https://doi.org/10.1016/j.amsu.2020.07.054Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.